The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,746.00
Bid: 4,732.00
Ask: 4,736.00
Change: 70.00 (1.50%)
Spread: 4.00 (0.085%)
Open: 4,676.00
High: 4,857.00
Low: 4,666.00
Prev. Close: 4,676.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic review of PT&IC businesses

5 May 2021 07:00

RNS Number : 5331X
Croda International PLC
05 May 2021
 

Press Release

5 May 2021

 

Strategic review of Performance Technologies & Industrial Chemicals businesses

Croda International Plc ("Croda" or the "Group"), which uses smart science to create high performance ingredients and technologies that improve lives, announces a strategic review of its Performance Technologies and Industrial Chemicals ('PTIC') businesses. The core objective will be to establish what ownership structure best serves this part of Croda's business going forward, to create a stronger platform for its future growth. The review is consistent with Croda's prioritisation of investments in faster-growth life science and consumer markets, which now represent over 80% of the Group's profitability.

PTIC is an excellent, world-leading business, with an impressive financial track record. It delivers industry-leading margins across the cycle through well invested manufacturing, innovation and sales operations, supported by a dedicated and experienced global team. It has a highly attractive portfolio, offering customers innovative, sustainable solutions in advanced technologies, and is focused on fast-growth markets in the circular plastic economy, electric vehicles and other renewable technologies. This strong technology portfolio supports PTIC's leading market positions in automotive, polymer and food packaging applications.

The scope of the strategic review will focus on the businesses and activities within PTIC that do not directly support the Consumer Care and Life Sciences sectors. It will consider whether Croda is the best future owner of all the PTIC businesses within the context of opportunities to deploy more capital and resources within PTIC, as well as in Consumer Care and Life Sciences.

The review will assess whether the full potential of PTIC can best be delivered under Croda, as a stand-alone business, or via a full or partial divestment. It will consider the extent of the mutual dependencies between PTIC and the rest of Croda, the practicality of all options, whilst prioritising the best interests of all stakeholders, including employees, customers and shareholders.

The review is expected to conclude by the end of 2021 and, in the meantime, the Group will continue to deliver an excellent service for its customers.

The strategic review is being launched in the context of ongoing improvement in Group trading year to date, continuing the trend seen in the second half of 2020. Customer demand is strong across all regions and sectors, including PTIC, in some cases driven by a recovery in end-consumer demand, in other areas by customer inventory build ahead of anticipated economic recovery. The Group will announce its Half Year Results to 30 June on 27 July 2021.

Further information

 

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQZLFBFELEBBQ
Date   Source Headline
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:00 amRNSDirector/PDMR Shareholding
6th Mar 20199:58 amRNSDirector/PDMR Shareholding
6th Mar 20199:57 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSResults for the year ended 31 December 2018
12th Feb 20194:47 pmRNSDirector/PDMR Shareholding
11th Jan 20194:21 pmRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSAcquisition completion
17th Dec 20187:00 amRNSAcquisition of global vaccine adjuvant specialist
12th Dec 20181:14 pmRNSDirector/PDMR Shareholding
22nd Nov 20181:54 pmRNSDirector Declaration
22nd Nov 20188:07 amRNSDirector/PDMR Shareholding
14th Nov 20182:48 pmRNSDirector/PDMR Shareholding
14th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSTrading Update for the Third Quarter 2018
26th Oct 20187:00 amRNSAcquisition update
12th Oct 20181:42 pmRNSDirector/PDMR Shareholding
4th Oct 20183:03 pmRNSDirector/PDMR Shareholding
4th Oct 20183:01 pmRNSDirector/PDMR Shareholding
28th Sep 20183:35 pmRNSDirector/PDMR Shareholding
11th Sep 20184:50 pmRNSDirector/PDMR Shareholding
6th Sep 20184:07 pmRNSDirector/PDMR Shareholding
5th Sep 20187:00 amRNSAppointment of Broker
22nd Aug 201811:06 amRNSDirector Declaration
13th Aug 20184:37 pmRNSDirector/PDMR Shareholding
7th Aug 20189:11 amRNSDirector/PDMR Shareholding
31st Jul 20184:16 pmRNSDirector/PDMR Shareholding
25th Jul 20184:19 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20182:27 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSDirector/PDMR Shareholding
12th Jun 20184:04 pmRNSDirector/PDMR Shareholding
11th Jun 20182:02 pmRNSDirector/PDMR Shareholding
31st May 20183:41 pmRNSDirector/PDMR Shareholding
25th May 20182:09 pmRNSDirector/PDMR Shareholding
11th May 20184:31 pmRNSDirector/PDMR Shareholding
26th Apr 20183:57 pmRNSDirector/PDMR Shareholding
26th Apr 20189:16 amRNSResult of AGM
25th Apr 20187:00 amRNSTrading Update for the First Quarter 2018
20th Apr 201811:14 amRNSDirectorate Change
20th Apr 20187:00 amRNSDirectorate Change
19th Apr 20189:47 amRNSDirector/PDMR Shareholding
19th Apr 20189:44 amRNSDirector/PDMR Shareholding
11th Apr 20181:09 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSCapital Markets Event
3rd Apr 20182:19 pmRNSDirector/PDMR Shareholding
28th Mar 20182:39 pmRNSDirector/PDMR Shareholding
28th Mar 20182:38 pmRNSDirector/PDMR Shareholding
28th Mar 201812:19 pmRNSScheme of Arrangement becomes Effective

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.